Amgen is enlisting AI startup PostEra for a drug discovery deal for five small molecule programs, PostEra announced Thursday morning.
Few details about the collaboration were made available. PostEra CEO Aaron Morris declined to comment on the deal value in an interview with Endpoints News. However, he described it as…
Click here to view original post
